Evidence map›Paper›PMID 40744408›Full record

ArticleNeuropharmacology2025

Striatal GluN2A gene suppression reduces L-DOPA-induced abnormal involuntary movements in parkinsonian rats.

Taiki Yabumoto, Brik A Kochoian, Stefano Coletta, Oskar Laur, Xinping Huang, Cassandra A Bure, Christopher Ware, Peng Jin, Stephen F Traynelis, Stella M Papa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Taiki YabumotoEmory National Primate Research Center, Emory University, Atlanta, 30329, Georgia. Electronic address: tyabumoto@live.jp.
Brik A KochoianEmory National Primate Research Center, Emory University, Atlanta, 30329, Georgia. Electronic address: bkochoi@emory.edu.
Stefano ColettaEmory National Primate Research Center, Emory University, Atlanta, 30329, Georgia. Electronic address: stefano.coletta@emory.edu.
Oskar LaurDepartment of Microbiology/Immunology and Emory Integrated Genomics Core, Emory University School of Medicine, Atlanta, 30322, Georgia. Electronic address: oliaur@emory.edu.
Xinping HuangDepartment of Neurology, Emory University School of Medicine, Atlanta, 30322, Georgia. Electronic address: xhuang4@emory.edu.
Cassandra A BureEmory National Primate Research Center, Emory University, Atlanta, 30329, Georgia. Electronic address: cabure@emory.edu.
Christopher WareEmory National Primate Research Center, Emory University, Atlanta, 30329, Georgia. Electronic address: christopher.bryson.ware@emory.edu.
Peng JinDepartment of Human Genetics, Emory University School of Medicine, Atlanta, 30322, Georgia. Electronic address: peng.jin@emory.edu.
Stephen F TraynelisDepartment of Pharmacology, Emory University School of Medicine, Atlanta, 30322, Georgia. Electronic address: strayne@emory.edu.
Stella M PapaEmory National Primate Research Center, Emory University, Atlanta, 30329, Georgia; Department of Neurology, Emory University School of Medicine, Atlanta, 30322, Georgia. Electronic address: spapa@emory.edu.

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Glutamate receptors and human neurological diseaseR35NS111619 · NINDS · EMORY UNIVERSITY · PI Stephen F Traynelis · 2019 to 2026
$6.6M
Regulation of Motor Function in Parkinson's DiseaseR01NS045962 · NINDS · EMORY UNIVERSITY · PI PAPA, STELLA M, TRAYNELIS, STEPHEN F · 2004 to 2022
$5.2M
Gene therapy targeting striatal dysfunction for Parkinson’s diseaseR01NS126924 · NINDS · EMORY UNIVERSITY · PI Stella M Papa · 2022 to 2026
$2.7M
Regulation of Motor Function in Parkinson's DiseaseR56NS045962 · NINDS · EMORY UNIVERSITY · PI PAPA, STELLA M, TRAYNELIS, STEPHEN F · 2018 to 2018
$603k
A novel gene therapy for motor symptoms of Parkinson's diseaseR21NS110416 · NINDS · EMORY UNIVERSITY · PI PAPA, STELLA M · 2019 to 2019
$483k
NIH HHS P51 OD011132NINDS NIH HHS R01 NS045962NINDS NIH HHS R01 NS126924NINDS NIH HHS R21 NS110416NINDS NIH HHS R35 NS111619NINDS NIH HHS R56 NS045962
6 · The paper itself

Abstract

L-DOPA-induced dyskinesia (LID) is a common disabling complication of long-term L-DOPA therapy in Parkinson's disease (PD). LID development is associated with maladaptive plasticity mechanisms in striatal circuits contributed by dysregulated dopamine and glutamate signaling. Upregulation of the NMDAR subunit 2A (GluN2A) over chronic L-DOPA treatment is thought to play a role in corticostriatal synaptic changes. We investigated the motor effects of selective GluN2A gene silencing by injecting a shRNA vector in the striatum of hemiparkinsonian rats. Striatal GluN2A knockdown significantly reduced abnormal involuntary movements (AIMs) while sustaining the therapeutic benefit of L-DOPA. These findings suggest that targeted adjustments of striatal NMDAR subunit composition may be a promising strategy for managing the long-term therapy of PD.

Indexed as

Antiparkinson AgentsCorpus StriatumDyskinesia, Drug-InducedLevodopaParkinsonian DisordersReceptors, N-Methyl-D-AspartateAnimalsDisease Models, AnimalMaleOxidopamineRatsRats, Sprague-DawleyRNA, Small InterferingAntiparkinson AgentsLevodopaOxidopamineReceptors, N-Methyl-D-AspartateRNA, Small Interfering

Identifiers

PMID40744408
PMCPMC12377408

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.